Omega-3 fatty acids protect brain function of Alzheimer’s disease patients

Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study.

SPMs (“specialized pro-resolving mediators”) are a group of compounds that are derived from omega-3 and omega-6 fatty acids. They have been shown to reduce inflammation, which is why they also have beneficial effects on Alzheimer's disease. This disease is associated with brain inflammation and reduced levels of SPMs. The present study evaluated the effects of omega-3 fatty acids (docosahexaenoic acid, DHA, and eicosapentaenoic acid, EPA) in Alzheimer´s disease patients. The study participants were given either a placebo or a supplement of 1.7 g DHA and 0.6 g EPA daily for 6 months. The results showed that supplementation with omega-3 fatty acids prevented a reduction in SPMs, which was associated with changes in brain function. Further details can be found in the study.
Wang X, Hjorth E, Vedin I, Eriksdotter M, Freund-Levi Y, Wahlund LO, Cederholm T, Palmblad J, Schultzberg M. Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res. 2015 Mar;56(3):674-81.



Leave a Reply